Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Sees Blockbuster Chronic Cough Opportunity With $2bn Bellus Buyout

Potential Best-In-Class Drug

Executive Summary

GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.

You may also be interested in...



AI In Cough Diagnosis: Making A Vicious Cycle Virtuous

Hyfe is extending AI to acoustics and championing technology it claims can transform the approach to cough management, leading to improved diagnoses, better treatment and superior health outcomes. CMO Peter Small explained the rationale and how AI has inspired a significant leap forward.

How To Be An Early-Stage Biotech CEO In Challenging Times

The ongoing downturn is making early-stage biotech leaders work harder to gain funding – but new technology, business focus and better working practices could help them achieve success. 

Vaccines Helped GSK Post Strong Q1 Results Ahead Of RSV Approval

Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel